Immunovant Analyst Price Targets

Wall Street analyst price targets and consensus rating for Immunovant (IMVT).

Price Target Range — 13 Quarters

Analyst Consensus — 15 Analysts

12Buy

3Hold

Consensus RatingBuy# Analysts15Avg. Consensus PT$43Upside to Avg. PT-1.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 4, 2026	JP Morgan	Brian Cheng	PT Raise	Overweight	$47→$50
Jun 30, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$57→$61
May 26, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$44→$62
May 22, 2026	Truist Securities	Danielle Brill	PT Raise	Hold	$23→$30
May 21, 2026	B of A Securities	Jason Gerberry	PT Raise	Buy	$32→$43
May 21, 2026	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$35→$40
Apr 15, 2026	Goldman Sachs	Corinne Johnson	PT Raise	Neutral	$29→$32
Feb 10, 2026	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$35
Feb 9, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$41→$44
Jan 8, 2026	Truist Securities	Danielle Brill	PT Raise	Hold	$16→$22
Jan 6, 2026	Wolfe Research	Andy Chen	Upgrade	Peer Perform→Outperform	$50
Dec 15, 2025	Goldman Sachs	Corinne Johnson	PT Raise	Neutral	$18→$28
Oct 14, 2025	Truist Securities	Danielle Brill	Initiate	Hold	$16
Sep 30, 2025	JP Morgan	Brian Cheng	PT Cut	Overweight	$37→$33
Sep 4, 2025	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$35
Aug 12, 2025	JP Morgan	Brian Cheng	PT Cut	Overweight	$40→$37
Aug 12, 2025	B of A Securities	Jason Gerberry	PT Cut	Buy	$33→$30
Jul 28, 2025	UBS	Ashwani Verma	PT Raise	Neutral	$17→$18
Apr 22, 2025	UBS	Colin Bristow	Downgrade	Buy→Neutral	$38→$17
Mar 20, 2025	Guggenheim	Yatin Suneja	Maintained	Buy	—